O1-10-06: Internet-based recruitment of subjects for prodromal and secondary prevention Alzheimer's disease trials using the brain health registry

2015 ◽  
Vol 11 (7S_Part_3) ◽  
pp. P156-P156
Author(s):  
Rachel L. Nosheny ◽  
Derek Flennkiken ◽  
Philip S. Insel ◽  
Shannon Finley ◽  
Scott Mackin ◽  
...  
2016 ◽  
Vol 12 (9) ◽  
pp. 1014-1021 ◽  
Author(s):  
Hugo Geerts ◽  
Penny A. Dacks ◽  
Viswanath Devanarayan ◽  
Magali Haas ◽  
Zaven S. Khachaturian ◽  
...  

2020 ◽  
Vol 12 (2) ◽  
pp. 996-1002
Author(s):  
Bimo Husodo

Abstract. Coffee is one of the most consumed beverages in the world and most adults drink coffee every day. Coffee contains hundreds of bioactive compounds, including caffeine, chlorogenic acid, polyphenols, and small amounts of minerals and vitamins, which are known to have positive effects on brain health. Alzheimer's disease is a degenerative disease of the brain and the most common cause of dementia characterized by decreased memory, language, problem solving and other cognitive skills that affect a person's ability to perform daily activities. The purpose of this literature study is to determine the benefits of coffee consumption in preventing Alzheimer's disease. Method. This research is a literature study and library sources used involving 15 libraries from 1 national journal and 14 international journals. Result. Several studies have shown the preventive effects of coffee on Alzheimer's disease and cognitive decline through various mechanisms such as a role in lowering plasma Aβ levels, as well as an antioxidant that can reduce inflammation and protect against dementia. Conclusion. Coffee can have a protective effect on Alzheimer's disease and is safe to consume if it does not exceed the recommended dosage. Abstract. Kopi adalah salah satu minuman yang paling banyak dikonsumsi di dunia dan sebagian besar or ang dewasa minum kopi setiap hari. Kopi mengandung ratusan senyawa bioaktif, termasuk kafein, asam klorogenat, polifenol, dan sejumlah kecil mineral dan vitamin yang di antaranya diketahui memiliki efek positif bagi kesehatan otak. Penyakit Alzheimer adalah penyakit degeneratif pada otak dan penyebab paling umum dari demensia yang ditandai dengan penurunan daya ingat, bahasa, pemecahan masalah, dan keterampilan kognitif lain yang memengaruhi kemampuan seseorang untuk melakukan aktivitas sehari-hari. Tujuan dari studi literatur ini adalah untuk mengetahui manfaat konsumsi kopi untuk mencegah penyakit Alzheimer.  Metode. Penelitian ini merupakan studi literatur dan sumber pustaka yang digunakan melibatkan 15 pustaka yang berasal dari 1 jurnal nasional dan 14 jurnal internasional. Hasil. Beberapa studi menunjukkan efek pencegahan dari kopi pada penyakit Alzheimer dan penurunan kognitif melalui berbagai mekanisme misalnya berperan dalam penurunan kadar Aβ plasma,serta sebagai antioksidan yang dapat mengurangi peradangan dan melindungi dari demensia. Kesimpulan. Kopi dapat memberikan efek protektif pada penyakit alzheimer serta aman dikonsumsi apabila tidak melebihi dosis yang dianjurkan


Author(s):  
Charles Alessi ◽  
Larry W. Chambers ◽  
Muir Gray

Our experience is that many people including many members of the medical profession are confused about what happens to our brains and minds as we live longer. Consistently, they overestimate the effects of ageing and underestimate the potential for improving the ability of the brain and the mind no matter what age you may be. Linked to this is the fact that, although Alzheimer’s disease cannot be prevented, the risk of dementia can be reduced by at least a third because there are many other causes of dementia than Alzheimer’s disease having to do with healthy brain tissue, blood supply to the brain and ability to interact with people and ideas. With this knowledge, we outline steps individuals can take themselves, with family and friends, their community and the health service to improve brain health.


GeroPsych ◽  
2012 ◽  
Vol 25 (4) ◽  
pp. 235-245 ◽  
Author(s):  
Katja Franke ◽  
Christian Gaser

We recently proposed a novel method that aggregates the multidimensional aging pattern across the brain to a single value. This method proved to provide stable and reliable estimates of brain aging – even across different scanners. While investigating longitudinal changes in BrainAGE in about 400 elderly subjects, we discovered that patients with Alzheimer’s disease and subjects who had converted to AD within 3 years showed accelerated brain atrophy by +6 years at baseline. An additional increase in BrainAGE accumulated to a score of about +9 years during follow-up. Accelerated brain aging was related to prospective cognitive decline and disease severity. In conclusion, the BrainAGE framework indicates discrepancies in brain aging and could thus serve as an indicator for cognitive functioning in the future.


PIERS Online ◽  
2009 ◽  
Vol 5 (4) ◽  
pp. 311-315 ◽  
Author(s):  
Natalia V. Bobkova ◽  
Vadim V. Novikov ◽  
Natalia I. Medvinskaya ◽  
Irina Yu. Aleksandrova ◽  
Eugenii E. Fesenko

Author(s):  
Burbaeva G.Sh. ◽  
Androsova L.V. ◽  
Vorobyeva E.A. ◽  
Savushkina O.K.

The aim of the study was to evaluate the rate of polymerization of tubulin into microtubules and determine the level of colchicine binding (colchicine-binding activity of tubulin) in the prefrontal cortex in schizophrenia, vascular dementia (VD) and control. Colchicine-binding activity of tubulin was determined by Sherlinе in tubulin-enriched extracts of proteins from the samples. Measurement of light scattering during the polymerization of the tubulin was carried out using the nephelometric method at a wavelength of 450-550 nm. There was a significant decrease in colchicine-binding activity and the rate of tubulin polymerization in the prefrontal cortex in both diseases, and in VD to a greater extent than in schizophrenia. The obtained results suggest that not only in Alzheimer's disease, but also in other mental diseases such as schizophrenia and VD, there is a decrease in the level of tubulin in the prefrontal cortex of the brain, although to a lesser extent than in Alzheimer's disease, and consequently the amount of microtubules.


2020 ◽  
Vol 17 ◽  
Author(s):  
Reem Habib Mohamad Ali Ahmad ◽  
Marc Fakhoury ◽  
Nada Lawand

: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the progressive loss of neurons leading to cognitive and memory decay. The main signs of AD include the irregular extracellular accumulation of amyloidbeta (Aβ) protein in the brain and the hyper-phosphorylation of tau protein inside neurons. Changes in Aβ expression or aggregation are considered key factors in the pathophysiology of sporadic and early-onset AD and correlate with the cognitive decline seen in patients with AD. Despite decades of research, current approaches in the treatment of AD are only symptomatic in nature and are not effective in slowing or reversing the course of the disease. Encouragingly, recent evidence revealed that exposure to electromagnetic fields (EMF) can delay the development of AD and improve memory. This review paper discusses findings from in vitro and in vivo studies that investigate the link between EMF and AD at the cellular and behavioural level, and highlights the potential benefits of EMF as an innovative approach for the treatment of AD.


2017 ◽  
Vol 14 (4) ◽  
pp. 441-452 ◽  
Author(s):  
Sofia Wenzler ◽  
Christian Knochel ◽  
Ceylan Balaban ◽  
Dominik Kraft ◽  
Juliane Kopf ◽  
...  

Depression is a common neuropsychiatric manifestation among Alzheimer’s disease (AD) patients. It may compromise everyday activities and lead to a faster cognitive decline as well as worse quality of life. The identification of promising biomarkers may therefore help to timely initiate and improve the treatment of preclinical and clinical states of AD, and to improve the long-term functional outcome. In this narrative review, we report studies that investigated biomarkers for AD-related depression. Genetic findings state AD-related depression as a rather complex, multifactorial trait with relevant environmental and inherited contributors. However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression. Regarding neuroimaging markers, the most promising findings reveal structural impairments in the cortico-subcortical networks that are related to affect regulation and reward / aversion control. Functional imaging studies reveal abnormalities in predominantly frontal and temporal regions. Furthermore, CSF based biomarkers are seen as potentially promising for the diagnostic process showing abnormalities in metabolic pathways that contribute to AD-related depression. However, there is a need for standardization of methodological issues and for replication of current evidence with larger cohorts and prospective studies.


2014 ◽  
Vol 13 (8) ◽  
pp. 1315-1324 ◽  
Author(s):  
Mohammad Ahmad ◽  
Javed Ahmad ◽  
Saima Amin ◽  
Mahfoozur Rahman ◽  
Mohammad Anwar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document